Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.
| Title: | Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis. |
|---|---|
| Authors: | Kho S; Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.; Seung KJ; Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.; Partners in Health, 800 Boylston Street Suite 300, Boston, MA, USA.; Huerga H; Epicentre, 14-34 Avenue Jean Jaurès, Paris, France.; Bastard M; Epicentre, 14-34 Avenue Jean Jaurès, Paris, France.; Khan PY; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.; Interactive Research and Development Global, Singapore, Singapore.; Mitnick CD; Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.; Partners in Health, 800 Boylston Street Suite 300, Boston, MA, USA.; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.; Rich ML; Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.; Partners in Health, 800 Boylston Street Suite 300, Boston, MA, USA.; Islam S; Interactive Research and Development, Dhaka, Bangladesh.; Zhizhilashvili D; Médecins sans Frontières, Tbilisi, Georgia.; Yeghiazaryan L; National Center for Pulmonology, Yerevan, Armenia.; Nikolenko EN; Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.; Zarli K; Médecins sans Frontières, Yangon, Myanmar.; Adnan S; Indus Hospital and Health Network, Karachi, Pakistan.; Salahuddin N; Indus Hospital and Health Network, Karachi, Pakistan.; Ahmed S; Interactive Research and Development, Karachi, Pakistan.; Vargas ZHR; Maria Auxiliadora Hospital, San Juan de Miraflores, Peru.; Bekele A; Department of Internal Medicine, Tikur Anbessa Specialized Hospital and Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.; Shaimerdenova A; Karaganda Regional Center of Phthisiopulmonology, Karaganda, Kazakhstan.; Tamirat M; Partners in Health, Lesotho, Maseru, Lesotho.; Gelin A; Zanmi Lasante, Port-au-Prince, Haiti.; Vilbrun SC; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.; Hewison C; Medical Department, Médecins sans Frontières, Paris, France.; Khan U; Interactive Research and Development Global, Singapore, Singapore.; Franke M; Partners in Health, 800 Boylston Street Suite 300, Boston, MA, USA. molly_franke@hms.harvard.edu.; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA. molly_franke@hms.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2024 May 09; Vol. 15 (1), pp. 3927. Date of Electronic Publication: 2024 May 09. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Observational Study; Research Support, N.I.H., Extramural; Multicenter Study |
| Language: | English |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : Nature Pub. Group |
| MeSH Terms: | Antitubercular Agents*/therapeutic use ; Antitubercular Agents*/pharmacology ; Sputum*/microbiology ; Tuberculosis, Multidrug-Resistant*/drug therapy ; Tuberculosis, Multidrug-Resistant*/microbiology ; Diarylquinolines*/therapeutic use ; Diarylquinolines*/pharmacology ; Oxazoles*/therapeutic use ; Nitroimidazoles*/therapeutic use ; Nitroimidazoles*/pharmacology; Mycobacterium tuberculosis/drug effects ; Humans ; Male ; Female ; Adult ; Middle Aged ; Prospective Studies ; Drug Repositioning |
| Abstract: | Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT03259269) to estimate the frequency (primary endpoint) among individuals receiving a longer (18-to-20 month) regimen for multidrug- or rifampicin-resistant (MDR/RR) TB who experienced culture conversion. We also conduct Cox proportional hazard regression analyses to identify factors associated with reversion, including comorbidities, previous treatment, cavitary disease at conversion, low body mass index (BMI) at conversion, time to conversion, and number of likely-effective drugs. Of 1,286 patients, 54 (4.2%) experienced reversion, a median of 173 days (97-306) after conversion. Cavitary disease, BMI |
| References: | Int J Tuberc Lung Dis. 2021 Jul 1;25(7):596-598. (PMID: 34183109); J Infect. 2017 Mar;74(3):260-271. (PMID: 27998752); Clin Infect Dis. 2013 Mar;56(6):770-6. (PMID: 23223591); Infect Genet Evol. 2017 Mar;48:76-82. (PMID: 27998730); BMC Infect Dis. 2019 Aug 20;19(1):733. (PMID: 31429722); PLoS One. 2018 Apr 11;13(4):e0193903. (PMID: 29641576); Int J Tuberc Lung Dis. 2006 Apr;10(4):402-8. (PMID: 16602404); Eur Respir J. 2016 Oct;48(4):1160-1170. (PMID: 27587552); Int J Tuberc Lung Dis. 2023 Jun 1;27(6):451-457. (PMID: 37231598); Emerg Infect Dis. 2015 Jun;21(6):992-1001. (PMID: 25993036); Clin Infect Dis. 2022 Sep 29;75(6):1006-1013. (PMID: 35028659); N Engl J Med. 2016 Sep 15;375(11):1103-5. (PMID: 27626539); Am J Respir Crit Care Med. 2021 Jan 1;203(1):111-119. (PMID: 32706644); J Infect Public Health. 2013 Dec;6(6):456-64. (PMID: 23999345); J Hepatol. 2020 May;72(5):1028-1029. (PMID: 32147086); Int J Tuberc Lung Dis. 2002 Mar;6(3):238-45. (PMID: 11934142); Int J Tuberc Lung Dis. 2023 Jan 1;27(1):34-40. (PMID: 36853128); PLoS One. 2022 Nov 10;17(11):e0276457. (PMID: 36355658); Open Forum Infect Dis. 2021 Jan 04;8(2):ofaa653. (PMID: 33634203); N Engl J Med. 2014 Aug 21;371(8):723-32. (PMID: 25140958); Int J Tuberc Lung Dis. 2011 Oct;15(10):1315-22. (PMID: 22283887); Am J Respir Crit Care Med. 2008 Nov 15;178(10):1075-82. (PMID: 18703792); Tuberculosis (Edinb). 2012 Sep;92(5):397-403. (PMID: 22789497); Clin Infect Dis. 2019 Apr 24;68(9):1522-1529. (PMID: 30165431); PLoS One. 2018 Jul 19;13(7):e0200539. (PMID: 30024924); BMC Infect Dis. 2020 Aug 24;20(1):622. (PMID: 32831044); Ann Intern Med. 2006 May 2;144(9):650-9. (PMID: 16670134); Eur Respir J. 2016 Feb;47(2):564-74. (PMID: 26647431); Lancet Respir Med. 2015 Mar;3(3):201-9. (PMID: 25726085); Eur Respir J. 2021 Aug 19;58(2):. (PMID: 34413124) |
| Grant Information: | R01 AI146095 United States AI NIAID NIH HHS |
| Substance Nomenclature: | 78846I289Y (bedaquiline); 0 (Antitubercular Agents); 0 (Diarylquinolines); 0 (Oxazoles); 0 (OPC-67683); 0 (Nitroimidazoles) |
| Entry Date(s): | Date Created: 20240509 Date Completed: 20240509 Latest Revision: 20260306 |
| Update Code: | 20260306 |
| PubMed Central ID: | PMC11082252 |
| DOI: | 10.1038/s41467-024-48077-8 |
| PMID: | 38724531 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't; Observational Study; Research Support, N.I.H., Extramural; Multicenter Study